Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.

MLA

Furubayashi, Nobuki, et al. “Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.” Anticancer Research, vol. 43, no. 10, Oct. 2023, pp. 4701–08. EBSCOhost, https://doi.org/10.21873/anticanres.16666.

APA

Furubayashi, N., Minato, A., Negishi, T., Sakamoto, N., Song, Y., Hori, Y., Tomoda, T., Masaoka, H., Harada, M., Tamura, S., Kobayashi, H., Morihara, K., Kuroiwa, K., Seki, N., Fujimoto, N., & Nakamura, M. (2023). Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study. Anticancer Research, 43(10), 4701–4708. https://doi.org/10.21873/anticanres.16666

Chicago

Furubayashi, Nobuki, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, Yoohyun Song, Yoshifumi Hori, Toshihisa Tomoda, et al. 2023. “Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.” Anticancer Research 43 (10): 4701–8. doi:10.21873/anticanres.16666.